Report Feature
The future of the global gene therapy market looks promising with opportunities in the oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, and infectious disease. The global gene therapy market is expected to grow with a CAGR of 27%-29% from 2020 to 2025. The major drivers for this market are increasing government support for R&D activities, rising awareness of people towards gene therapy, and increasing prevalence of cancer.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global gene therapy market report, please download the report brochure.
In this market, non-viral vectors is the largest vector of gene therapy, whereas oncological disorder is the largest application. Growth in various segments of the gene therapy market are given below:
The study includes trends and forecast for the global gene therapy market by gene type, application, vector, indication, delivery method, and region as follows:
By Gene Type [Value ($ Million) shipment analysis for 2014 – 2025]:
- Antigen
- Cytokine
- Tumor Suppressor
- Suicide
- Deficiency
- Growth Factors
- Receptors
- Others
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
- Oncological Disorders
- Rare Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Infectious Disease
- Other Diseases
By Vector [Value ($ Million) shipment analysis for 2014 – 2025]:
-
Non-Viral Vectors
- Oligonucleotides
- Other Non-Viral Vectors
-
Viral Vectors
- Retroviral Vectors
- Adeno-Associated Virus Vectors
- Other Viral Vectors
By Indication [Value ($ Million) shipment analysis for 2014 – 2025]:
- Neurological Diseases
- Cancer
- Hepatological Diseases
- Duchenne Muscular Dystrophy
- Other Indications
By Delivery Method [Value ($ Million) shipment analysis for 2014 – 2025]:
- In Vivo Gene Therapy
- Ex Vivo Gene Therapy
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
-
North America
- United States
- Canada
- Mexico
-
Europe
- United Kingdom
- Germany
- France
-
Asia Pacific
- China
- India
- Japan
-
The Rest of the World
- Brazil
Some of the gene therapy companies profiled in this report include Biogen, Novartis AG, Gilead Sciences, Spark Therapeutics, MolMed S.p.A., Orchard Therapeutics, SIBIONO, Shanghai Sunway Biotech, bluebird bio, and Human Stem Cells Institute.
Lucintel forecasts that non-viral vectors will remain the largest segment over the forecast period due to increasing demand of oligonucleotide-based non-viral vector gene therapies and advancements in physicochemical approaches for gene therapies during preclinical and clinical trials.
Within this market, oncological disorder will remain the largest segment by application over the forecast period due to increasing prevalance of cancer.
North America will remain the largest region over the forecast period due to high disposable incomes, increasing prevalance of chronic diseases, and growing healthcare expenditure in the region.
|
Features of the Global Gene Therapy Market |
|
|
This report answers following key questions |
|
Q.1 What are some of the most promising potential, high-growth opportunities for the global gene therapy market by gene type (antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others), application (oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases), vector (non-viral vectors (oligonucleotides and other non-viral vectors) and viral vectors (retroviral vectors, adeno-associated virus vectors, and other viral vectors)), indication (neurological diseases, cancer, hepatological diseases, duchenne muscular dystrophy, and other indications), delivery method (in vivo gene therapy and ex vivo gene therapy), and region (North America, Europe, Asia Pacific, and Rest of the World)? Q.2 Which segments will grow at a faster pace and why? Q.3 Which region will grow at a faster pace and why? Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global gene therapy market? Q.5 What are the business risks and threats to the global gene therapy market? Q.6 What are the emerging trends in this gene therapy market and the reasons behind them? Q.7 What are some changing demands of customers in this gene therapy market? Q.8 What are the new developments in this gene therapy market? Which companies are leading these developments? Q.9 Who are the major players in this gene therapy market? What strategic initiatives are being implemented by key players for business growth? Q.10 What are some of the competitive products and processes in this gene therapy market, and how big of a threat do they pose for loss of market share via material or product substitution? Q.11 What M&A activities did take place in the last five years in the global gene therapy market? |
Report Scope
| Key Features | Description |
| Base Year for Estimation | 2019 |
|
Trend Period (Actual Estimates) |
2014-2019 |
| Forecast Period | 2020-2025 |
| Pages | More than 150 |
| Market Representation / Units | Revenue in US $ Million |
| Report Coverage | Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling |
| Market Segments | Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases), Vector (Non-Viral Vectors and Viral Vectors), Indication (Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications), and Delivery Method (In Vivo Gene Therapy and Ex Vivo Gene Therapy) |
Regional Scope |
North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil) |
| Customization | 10% Customization without Any Additional Cost |
Table of Contents
1. Executive Summary
7.2 Emerging Trends in the Global Gene Therapy Market
3.1 Macroeconomic Trends and Forecast
3.2 Global Gene Therapy Market Trends and Forecast
3.3.1 Antigen
3.3.2 Cytokine
3.3.3 Tumor Suppressor
3.3.4 Suicide
3.3.5 Deficiency
3.3.6 Growth Factors
3.3.7 Receptors
3.3.8 Others
3.4.1 Oncological Disorders
3.4.2 Rare Diseases
3.4.3 Cardiovascular Diseases
3.4.4 Neurological Disorders
3.4.5 Infectious Disease
3.4.6 Other Diseases
3.5.1 Non-Viral Vectors
3.5.2 Viral Vectors
3.6.1 Neurological Diseases
3.6.2 Cancer
3.6.3 Hepatological Diseases
3.6.4 Duchenne Muscular Dystrophy
3.6.5 Other Indications
3.7.1 In Vivo Gene Therapy
3.7.2 Ex Vivo Gene Therapy
4.1 Global Gene Therapy Market by Region
4.2.1 Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.2.2 Market byApplication: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.2.3 Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.2.4 Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.2.5 Market by Delivery Method: In Vivo Gene Therapy and Ex Vivo Gene Therapy
4.2.6 The United States Gene Therapy Market
4.2.7 The Canadian Gene Therapy Market
4.2.8 The Mexican Gene Therapy Market
4.3.1 Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.3.2 Market by Application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.3.3 Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.3.4 Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.3.5 Market by Delivery Method: In Vivo Gene Therapy and Ex Vivo Gene Therapy
4.3.6 The Gene Therapy Market of United Kingdom
4.3.7 The German Gene Therapy Market
4.3.8 The French Gene Therapy Market
4.4.1 Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.4.2 Market byApplication: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.4.3 Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.4.4 Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.4.5 Market by Delivery Method: In Vivo Gene Therapy and Ex Vivo Gene Therapy
4.4.6 The Chinese Gene Therapy Market
4.4.7 The Indian Gene Therapy Market
4.4.8 The Japanese Gene Therapy Market
4.5.1 Market by Gene Type: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others
4.5.2 Market by Application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases
4.5.3 Market by Vector: Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors) and Viral Vectors (Retroviral Vectors, Adeno-Associated Virus Vectors, and Other Viral Vectors
4.5.4 Market by Indication: Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Other Indications
4.5.5 Market by Delivery Method: In Vivo Gene Therapy and Ex Vivo Gene Therapy
4.5.6 Brazilian Gene Therapy Market
7.1.1 Growth Opportunities for the Global Gene Therapy Market by Gene Type
7.1.2 Growth Opportunities for the Global Gene Therapy Market by Application
7.1.3 Growth Opportunities for the Global Gene Therapy Market by Vector
7.1.4 Growth Opportunities for the Global Gene Therapy Market by Indication
7.1.5 Growth Opportunities for the Global Gene Therapy Market by Delivery Method
7.1.6 Growth Opportunities for the Global Gene Therapy Market by Region
Methodology
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in this market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Buy Now
Choose a license that fits your team. Instant PDF delivery.
Prices exclude taxes. Instant delivery. Custom licensing available on request.
